| Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study S Blach, S Zeuzem, M Manns, I Altraif, AS Duberg, DH Muljono, I Waked, ... The lancet Gastroenterology & hepatology 2 (3), 161-176, 2017 | 1116 | 2017 |
| Epidemiology and natural history of HCV infection B Hajarizadeh, J Grebely, GJ Dore Nature reviews Gastroenterology & hepatology 10 (9), 553, 2013 | 969 | 2013 |
| Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review L Degenhardt, A Peacock, S Colledge, J Leung, J Grebely, P Vickerman, ... The Lancet Global Health 5 (12), e1192-e1207, 2017 | 566 | 2017 |
| Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale‐up in the age of direct‐acting antivirals NK Martin, P Vickerman, J Grebely, M Hellard, SJ Hutchinson, VD Lima, ... Hepatology 58 (5), 1598-1609, 2013 | 497 | 2013 |
| Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States S Barua, R Greenwald, J Grebely, GJ Dore, T Swan, LE Taylor Annals of internal medicine 163 (3), 215-223, 2015 | 380 | 2015 |
| The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection J Grebely, K Page, R Sacks‐Davis, MS van der Loeff, TM Rice, J Bruneau, ... Hepatology 59 (1), 109-120, 2014 | 354 | 2014 |
| Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis EJ Aspinall, S Corson, JS Doyle, J Grebely, SJ Hutchinson, GJ Dore, ... Clinical Infectious Diseases 57 (suppl_2), S80-S89, 2013 | 326 | 2013 |
| Elbasvir–grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial GJ Dore, F Altice, AH Litwin, O Dalgard, EJ Gane, O Shibolet, ... Annals of internal medicine 165 (9), 625-634, 2016 | 297 | 2016 |
| Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression R Waziry, B Hajarizadeh, J Grebely, J Amin, M Law, M Danta, J George, ... Journal of hepatology 67 (6), 1204-1212, 2017 | 292 | 2017 |
| Global statistics on alcohol, tobacco and illicit drug use: 2017 status report A Peacock, J Leung, S Larney, S Colledge, M Hickman, J Rehm, ... Addiction 113 (10), 1905-1926, 2018 | 283 | 2018 |
| Potential role for Interleukin‐28B genotype in treatment decision‐making in recent hepatitis C virus infection J Grebely, K Petoumenos, M Hellard, GV Matthews, V Suppiah, ... Hepatology 52 (4), 1216-1224, 2010 | 233 | 2010 |
| Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review S Larney, A Peacock, J Leung, S Colledge, M Hickman, P Vickerman, ... The Lancet Global Health 5 (12), e1208-e1220, 2017 | 217 | 2017 |
| Barriers associated with the treatment of hepatitis C virus infection among illicit drug users J Grebely, KA Genoway, JD Raffa, G Dhadwal, T Rajan, G Showler, ... Drug and alcohol dependence 93 (1-2), 141-147, 2008 | 215 | 2008 |
| Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine J Grebely, M Prins, M Hellard, AL Cox, WO Osburn, G Lauer, K Page, ... The Lancet infectious diseases 12 (5), 408-414, 2012 | 200 | 2012 |
| Low uptake of treatment for hepatitis C virus infection in a large community‐based study of inner city residents J Grebely, JD Raffa, C Lai, M Krajden, T Kerr, B Fischer, MW Tyndall Journal of viral hepatitis 16 (5), 352-358, 2009 | 193 | 2009 |
| What is killing people with hepatitis C virus infection? J Grebely, GJ Dore Seminars in liver disease 31 (04), 331-339, 2011 | 186 | 2011 |
| Hepatitis C virus reinfection in injection drug users J Grebely, B Conway, JD Raffa, C Lai, M Krajden, MW Tyndall Hepatology 44 (5), 1139-1145, 2006 | 174 | 2006 |
| Effective treatment of injecting drug users with recently acquired hepatitis C virus infection GJ Dore, M Hellard, GV Matthews, J Grebely, PS Haber, K Petoumenos, ... Gastroenterology 138 (1), 123-135. e2, 2010 | 167 | 2010 |
| Prioritization of HCV treatment in the direct-acting antiviral era: an economic evaluation NK Martin, P Vickerman, GJ Dore, J Grebely, A Miners, J Cairns, ... Journal of hepatology 65 (1), 17-25, 2016 | 162 | 2016 |
| Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels J Grebely, M Oser, LE Taylor, GJ Dore The Journal of infectious diseases 207 (suppl_1), S19-S25, 2013 | 162 | 2013 |
